Anorexia News and Research

RSS

Study: Women with eating disorders are less likely to have children

Women with eating disorders are less likely to have children than others in the same age group, indicates a study conducted at the University of Helsinki, Finland. The likelihood for miscarriage was more than triple for binge-eating disorder (BED) sufferers and the likelihood of abortion more than double for bulimics than others in the same age group.

8 Oct 2013

Study shows certain brain cells play critical role in anorexia, bulimia, and binge eating disorder

Sixty years ago scientists could electrically stimulate a region of a mouse's brain causing the mouse to eat, whether hungry or not. Now researchers from UNC School of Medicine have pinpointed the precise cellular connections responsible for triggering that behavior.

27 Sep 2013

Exposure to cocaine during in utero development causes disruptions in normal brain development

Prenatal cocaine exposure affects both behavior and brain. Animal studies have shown that exposure to cocaine during in utero development causes numerous disruptions in normal brain development and negatively affects behavior from birth and into adulthood.

25 Sep 2013

Shadow of past highest weight affects eating disorder symptoms and recovery

Dieters and weight loss researchers are familiar with the principle: The more weight you've lost, the harder it is to keep it off. A complex and vicious cycle of biological and behavioral factors make it so.

25 Sep 2013

Higher calorie diets produce twice rate of weight gain for adolescents hospitalized with anorexia

Higher calorie diets produce twice the rate of weight gain compared to the lower calorie diets that currently are recommended for adolescents hospitalized with anorexia nervosa, according to a study by researchers at UCSF Benioff Children-s Hospital.

21 Sep 2013

Study shows anorexia linked to how cholesterol processes

The largest DNA-sequencing study of anorexia nervosa has linked the eating disorder to variants in a gene coding for an enzyme that regulates cholesterol metabolism. The finding suggests that anorexia could be caused in part by a disruption in the normal processing of cholesterol, which may disrupt mood and eating behavior.

12 Sep 2013

New research focuses on perfectionism to improve treatment for adolescent anorexia

Reducing ‘perfectionistic’ thinking as a way to improve treatment for adolescent anorexia, is the focus of new research by Griffith University.

28 Aug 2013

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

27 Aug 2013

Brain size can predispose person to develop eating disorders

New research indicates that teens with anorexia nervosa have bigger brains than teens that do not have the eating disorder. That is according to a study by researchers at the University of Colorado's School of Medicine that examined a group of adolescents with anorexia nervosa and a group without.

23 Aug 2013

Researchers find genetic correlation between eating disorders and alcohol dependence

Part of the risk for alcohol dependence is genetic, and the same is true for eating disorders. Now, researchers at Washington University School of Medicine in St. Louis have found it's likely some of the same genes are involved in both.

21 Aug 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

Hyperactivity due to ADHD are associated with worse prognosis in patients with eating disorders

A study made with 191 patients reveal that symptoms of hyperactivity due to the deficit of attention and hyperactivity disorder (ADHD) are associated with more impulsivity and more severity, and probably a worse prognosis in patients with eating disorders.

11 Jul 2013

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

1 Jul 2013

Estrogen replacement therapy reduces anxiety symptoms in girls with anorexia nervosa

Estrogen replacement therapy is associated with a significant decrease in anxiety symptoms among girls with anorexia nervosa, a new clinical trial finds. The results will be presented today at The Endocrine Society's Annual Meeting in San Francisco.

18 Jun 2013

European Commission amends marketing authorisation for Celgene's REVLIMID

Celgene International Sàrl was today notified that the European Commission has amended the marketing authorisation for REVLIMID. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

17 Jun 2013

Teva to present abstracts on AZILECT at MDS meeting

Teva Pharmaceutical Industries Ltd. announced today that a number of abstracts will be presented during the 17th Annual International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013, also known as the Movement Disorders Society.

15 Jun 2013

Brain circuits involved in compulsive behavior reveal a surprising connection with obesity

What started as an experiment to probe brain circuits involved in compulsive behavior has revealed a surprising connection with obesity.

11 Jun 2013

Altered function of neural circuitry contributes to bulimia and anorexia

Anorexia nervosa and bulimia nervosa -disorders characterized by extreme eating behavior and distorted body image - are among the deadliest of psychiatric disorders, with few proven effective treatments.

4 Jun 2013

Lightlake Therapeutics announces Phase II clinical trial results of nasal spray treatment for BED

Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.

23 May 2013